|
| Thursday, 14 May 2015, 09:36 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| Highlights Include New Clinical Data on Halaven (Eribulin) in Soft Tissue Sarcoma and on Lenvima (Lenvatinib) in Renal Cell Carcinoma |
TOKYO, May 14, 2015 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, "eribulin") and Lenvima (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 29 to June 2, 2015.
The main presentations for this year's ASCO meeting include an oral presentation highlighting the results of a Phase III clinical study (Study 309) of eribulin in soft tissue sarcoma to be given on Monday, June 1. Furthermore, these findings have been chosen by ASCO to be featured in a press conference as part of the official press program starting at 10:30 a.m. (CDT) on Saturday, May 30.
For lenvatinib, an oral presentation on the results of a Phase II clinical study (Study 205) of the agent in metastatic renal cell carcinoma will also be given on Monday, June 1.
In addition, the poster sessions include a presentation of the results of an analysis concerning biomarkers of response and resistance in the Phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT study).
Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.
Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
